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A B S T R A C T
Background: Relapses in Multiple Sclerosis (MS) are often associated with significant disability impairment
which is resultant from poor response to corticosteroids. In such severe cases, plasma exchange (PLEX) may be
used, although only a few studies with MS patients have been reported. Our objective was to evaluate the
effectiveness of PLEX in severe relapses of MS.
Methods: Retrospective study of MS patients treated with PLEX in acute relapses. Data regarding EDSS, an-
nualized relapse rate (ARR), treatment with corticosteroids, number of PLEX sessions, adverse events, and ga-
dolinium enhancement in brain MRI were analysed.
Results: Included 46 patients, 76.09% female (n = 35) with mean age of 38.76 years and mean disease duration
of 5.99 years, of which 84.78% had a Relapsing Remitting MS (n = 39), 15.22% Secondary Progressive MS (n =
7). The previous ARR was 1.1 and in 28.26% of the cases (n = 13) PLEX was used in the relapse that led to MS
diagnosis. The majority of relapses had motor impairment (69.6%, n = 32), with a median EDSS increase of 1.5
points from baseline (maximum of 6.5) and higher than 1.5 points in 45.65% of cases (n = 21). Brain MRI was
available in 69.57% of the cases (n = 32), and gadolinium enhancing lesions were present in 68.75% of cases (n
= 22). Corticosteroids were used before PLEX in all patients for a mean of 6.09 days, without any immediate
benefit in 41.30% of cases (n = 19), with the remaining cases showing only mild disability recovery. After a
mean of 7.39 PLEX sessions, there was clinical benefit with complete EDSS recovery in 41.30% of patients (n =
19), and partial in 39.13% (n = 18). There were no adverse events related to PLEX in 89.13% of patients (n =
41) and in the remaining patients the reported adverse events included deep venous thrombosis (n = 1),
anaemia (n = 1), fever (n = 1), hypoalbuminemia (n = 1) and arterial hypotension (n = 1).
Conclusion: Our results support the use of PLEX in severe relapses unresponsive to corticosteroids, since it was an
effective and relatively safe treatment for most of our patients.
1. Introduction
Multiple Sclerosis (MS) is the most common demyelinating in-
flammatory disease of the central nervous system (CNS), and the
leading cause of non-traumatic neurological disability in young adults
in North America and Europe, affecting more than two million people
worldwide (Dutta and Trapp 2011).
Most patients experience a relapsing remitting MS (RRMS), with
acute episodes of neurologic dysfunction named relapses, followed by
periods of partial or complete remission with clinical stability between
episodes, although patients with secondary progressive MS (SPMS) and
primary progressive MS (PPMS) may also experience relapses during
evolution of the disease (Confavreux et al., 2000; Lublin et al., 2014).
Although in the past 20 years an important progress has been made
in the field of multiple sclerosis treatment, the available treatments are
yet incapable of completely preventing relapse occurrence, and its
treatment is still a major component of the management of MS patients,
in all phases of the disease (Comi et al., 2017). Relapses with in-
complete remissions are an important contributor for the increase in
neurologic disability and decreased health-related quality of life, and
therefore aggressive relapse treatment is critical (Confavreux et al.,
2000; Berkovich, 2013).
The gold standard treatment for MS relapses are corticosteroids.
Several mechanisms have been proposed to justify its efficacy: decrease
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of oedema due to anti-inflammatory component; reduction of B-lym-
phocyte counts and their availability at the inflammatory lesions re-
sulting in a decreased number of immunoglobulin (Ig) G synthesizing
cells in the CNS; reduction of the blood–brain barrier abnormally in-
creased permeability resulting in less gadolinium enhancing lesions
(Berkovich, 2013; Frohman et al., 2007; Durelli et al., 1986; Martinelli
et al., 2009).
Frequently, severe relapses are unresponsive to corticosteroids and
in such cases, several options have been studied and used, such as
plasma exchange (PLEX), cyclophosphamide, intravenous im-
munoglobulin G (IVIG) and natalizumab (Berkovich, 2013).
Several reports of PLEX efficacy have been published and although
most studies have small cohorts and different evaluation methods, (Dau
et al., 1980; Valbonesi et al., 1981; Weiner et al., 1989; Palm et al.,
1991; Weinshenker et al., 1999; Weinshenker, 1999; Keegan et al.,
2002, 2005; Bennetto et al., 2004; Ruprecht et al., 2004; Schilling et al.,
2006; Linker et al., 2007; Llufriu et al., 2009; Trebst et al., 2009; Habek
et al., 2010; Roesner et al., 2012; Ehler et al., 2015; Ikeda et al., 2015;
Deschamps et al., 2016, 2017) due to the available evidence, European
and American guidelines consider that some patients with MS, who
have not responded to treatment with methylprednisolone may benefit
from PLEX (Sellebjerg et al., 2005; Cortese et al., 2011).
Our objective was to evaluate efficacy and safety of PLEX in a cohort
with severe relapses of MS refractory to corticosteroids treatment, in
order to reinforce its importance in the management of MS relapses.
2. Materials and methods
2.1. Participants
This was a retrospective study. The start date for inclusion was
January 1, 2000 and the last date for data introduction was 31
December 2015. The inclusion criteria were: patients followed in the
Neurology Department of our Portuguese University Hospital with the
diagnosis of RRMS (all patients met the criteria for diagnosis according
to the McDonald Criteria of 2010); (Polman et al., 2011) treatment with
Plasma Exchange (PLEX) during an acute relapse; and age above 18
years. Exclusion criteria were incomplete medical records.
This study was approved by the local ethics committee.
2.2. Clinical assessment
A relapse was defined as current patient-reported symptoms or
objectively observed signs, typical of an acute inflammatory demyeli-
nating event in the central nervous system, lasting at least 24 h, in the
absence of fever or infection (Polman et al., 2011).
Data regarding MS subtype, EDSS, annualized relapse rate (ARR),
previous and following treatment, treatment with corticosteroids,
number of PLEX sessions, adverse events, and gadolinium enhancement
in brain MRI were analysed.
2.3. MRI acquisition and analysis
Data from 1.5 T MRI reports were obtained. The presence of ga-
dolinium enhancement lesions in brain MRI was analysed.
2.4. Statistical analysis
Demographic characteristics were presented as means and standard
deviations for continuous variables, and as frequencies and percentages
for categorical variables. The ARR and the EDSS were described as the
mean and standard deviation. Safety outcomes were reported descrip-
tively. In our sample all the variables have a non-normal distribution, so
nonparametric tests were used. The Wilcoxon Signed Ranks Test was
used to compare related continuous and related ordinal samples, and
the Mann-Whitney Test is used to compare different groups of patients.
P values (2-tailed)< 0.05 were considered statistically significant; in
the graphs 95% confidence intervals were used.
3. Results
3.1. Demographic characteristics of the patients
Among the MS population regularly followed in our outpatient de-
partment (n = 1014 patients), 47 patients were treated with PLEX, of
which one was excluded due to incomplete medical records, with a final
population of 46 patients. Patient baseline characteristics are sum-
marized in Table 1.
The diagnosis of MS was performed in the relapse leading to PLEX
treatment in 28.26% of the cases (n = 13). In 23.91% of the cases (n =
11) patients were treated with fingolimod, natalizumab or other im-
munosuppressive therapies. In the particular case of other im-
munosuppressive therapies, azathioprine was used in two patients
(RRMS and SPMS) in 2007, micophenolate mofetil was used in one
RRMS patient in 2014, mitoxantrone was used in one RRMS patient in
2009, cyclophosphamide was used in one RRMS patient in 2007 and in
another with SPMS in 2014. These treatments were used in all cases
after approved disease modifying treatments failure.
3.2. PLEX in our cohort
3.2.1. Relapse characteristics
The relapse characteristics that led to PLEX may be consulted in
Table 2.
Table 1
Patient characteristics previous to PLEX treatment.
Female gender, % (n) 76.09% (n = 35)
Mean age, years (min-max, SD) 38.76 (19–71,
10.30)
Mean disease duration, years (min-max, SD) 5.99 (0–19, 6.0)
Subtype MS
• RRMS, % (n) 84.78% (n = 39)• SPMS, % (n) 15.22% (n = 7)
Annual relapse rate in the previous year, mean (min-max,
SD)
1.13 (0–4, 1.11)
Baseline EDSS, median (min-max, IQR) 2.49 (0–6.5, 2.9)
Baseline MS treatment
• Naïve - without previous MS diagnosis % (n) 28.26% (n = 13)• Glatiramer acetate, % (n) 13.04 (n = 6)• Interferon beta, % (n) 34.78 (n = 16)• Fingolimod, % (n) 8.70 (n = 4)• Natalizumab, % (n) 2.17 (n = 1)• Azathioprine, % (n) 4.35 (n = 2)• Micophenolate mofetil 2.17 (n = 1)• Mitoxantrone 2.17 (n = 1)• Cyclophosphamide 4.35 (n = 2)
Abbreviations: n – number; MS- Multiple Sclerosis; RRMS – relapsing-remitting multiple
sclerosis; min - minimum; max - maximum; SD - standard deviation; IQR – interquartile
range.
Table 2
Relapse characteristics that led to PLEX.
Symptoms
• Motor impairment, % (n) 47.83% (n = 22)• Severe optic neuritis, % (n) 4.35% (n = 2)• Ataxia, % (n) 4.35% (n = 2)• Brainstem symptoms, % (n) 4.35% (n = 2)• Multifocal symptoms, % (n) 39.13% (n = 18)
EDSS during relapse, median (min-max, IQR) 4.0 (1.5 – 8.0, 3.0)
EDSS increase during relapse, median (min-max, IQR) 1.5 (0 – 6.5, 2.0)
Gadolinium enhancing lesions in brain MRIa, % (n) 68.8% (n = 22)
Abbreviations: PLEX – plasma exchange; n – number; min - minimum; max - maximum;
IQR – interquartile range; MRI – magnetic resonance imaging.
a - MRI available in 32 patients.
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The majority of the cases experienced severe disability, with median
EDSS during relapse of 4.0, after a median increase of 1.5 points from
baseline (maximum of 6.5). In fact, the EDSS increased over 1.5 points
in 45.65% of the patients (n = 21), as reported in Fig. 1.
In 6.52% of the patients (n = 3) the impairment provoked by the
relapse did not lead to an increase in EDSS. One of these cases was a
patient with baseline EDSS of 3.0 who experienced a severe optic
neuritis without EDSS increase. The other two patients had a baseline
EDSS of 3.5 and 3.0 respectively, and experienced a worsening of
previous paraparesis without measured EDSS increase.
In the particular cases of previously undiagnosed patients, the
median EDSS during relapse was 3.5.
Brain MRI performed during the relapse was available in 69.57% of
the cases (n = 32). In those patients, gadolinium enhancing lesions
were present in 68.75% of cases (n = 22).
3.2.2. Relapse treatment before PLEX
All patients were previously treated with corticosteroids (methyl-
prednisolone 1 g administered intravenously once daily) before starting
PLEX.
The mean duration of corticosteroids treatment was 6.09 days and
treatment duration with methylprednisolone may be consulted in
Table 3.
Despite the treatment with corticosteroids, 41.30% of the patients
(n = 19) did not experienced any immediate benefit, and the remaining
cases had showed only mild disability recovery. In the subgroup of
patients without MS previously diagnosed, 30.77% (n = 4) did not
improve with corticosteroids, and the remaining only experienced
partial recovery.
3.2.3. PLEX treatment
PLEX was started after corticosteroids treatment in all patients, in
mean, 33.48 days after relapse onset (Table 4).
The distribution of patients according to the number of PLEX ses-
sions may be consulted in Table 4. One patient only performed one
session stopped the treatment due to the loss of the intravenous access.
The median EDSS after PLEX was 2.75 (minimum of 1.0 and max-
imum of 8.0, IQR 2.1).
Our population experienced recovery of neurological disability in
80.43% of the cases (n = 37) (Table 4). Considering the subgroup of
patients without MS previously diagnosed (n = 13), none of the
patients completely recovered immediately after PLEX, but partial re-
covery was achieved in 69.23% of the cases (n = 9).
Considering the different groups of response to PLEX, there was a
significant difference in the number of PLEX sessions between groups (p
= 0.010). The subgroup of patients who experienced complete dis-
ability recovery had the highest number of PLEX sessions (mean of 9.26
sessions), compared to those patients with partial recovery (mean of
7.17 sessions), and the number was even lower in those patients who
did not recover (mean of 5.78 sessions).
There were no other significant differences between groups, neither
regarding gender, disease duration, previous disease modifying treat-
ment, type of relapse or the presence of gadolinium enhancing lesions
on brain MRI. Regarding time to PLEX since relapse onset we found no
significant differences between groups, with disability recovery (partial
or complete) occurring in 83.33% of the patients who performed PLEX
during the first month after relapse onset (n = 30 of 36 patients), 60%
in the patients who performed PLEX during the second month after
relapse onset (n = 3 of 5 patients), 75% during the third month (n = 3
of 4 patients), and the patient who had PLEX after 4 months since re-
lapse onset experienced complete recovery.
Late response to PLEX was evaluated considering EDSS assessed one
year later, with improvement in EDSS of 10.87% of the patients (n = 5)
and stability in 80.44% of the patients (n = 37). Overall, although a
decrease in median EDSS was observed (2.5, minimum of 1.0 and
maximum of 8.0, IQR 2.5), it was not significantly different from the
EDSS evaluated immediately after PLEX.
After PLEX treatment, 47.82% (n = 22) of the patients who were
already under MS treatment (n = 33) changed the disease modifying
treatment. Considering the entire population, after this relapse 45.65%
(n = 21) of the patients were treated with natalizumab or fingolimod,
and 21.7% (n = 10) were treated with immunosuppressive drugs such
as cyclophosphamide (n = 4), rituximab (n = 3), and azathioprine (n
= 3).
3.2.4. PLEX related adverse events
PLEX was a safe treatment for most of the patients since there were
no adverse events reported in 89.13% of the patients (n = 41).
In the remaining patients, a few adverse events were reported. One
patient experienced deep venous thrombosis after 14 sessions, leading
to PLEX suspension. It was not necessary to stop PLEX in the other
patients with side effects, which were: mild anaemia (n = 1), transient
fever (n = 1), hypoalbuminemia corrected with intravenous reposition
of albumin without PLEX discontinuation (n = 1) and arterial hypo-
tension without complications or PLEX discontinuation (n = 1).
Fig. 1. Distribution of patients according to the disability increase measured by EDSS
points during relapse.
Table 3
Methylprednisolone treatment before PLEX.
Mean treatment duration, days (SD) 6.09 (1.94)
3–4 days, n (%) 3 (6.52)
5 days, n (%) 26 (56.52)
7 days, n (%) 10 (21.74)
2 cycles of treatment (5 days each), n (%) 7 (15.22)
Abbreviations: PLEX – plasma exchange; SD – standard deviation; n – number.
Table 4
Treatment with PLEX.
Treatment initiation since relapse onset
• Mean duration, days (min-max, SD) 33.48 (10 – 120, 24.22)• 2nd week, n (%) 9 (19.57)• 3rd–4th week, n (%) 9 (19.57)• 5th– 6th week, n (%) 20 (43.48)• 3rd month, n (%) 5 (10.87)• 4th month, n (%) 2 (4.35)• 5th month, n (%) 1 (2.17)
Number of PLEX sessions (every other day)
• Mean (min-max, SD) 7.39 (1 – 14, 2.79)• 1–6, n (%) 17 (36.96)• 7–10, n (%) 26 (56.52)• 11–14, n (%) 3 (6.52)
Disability recovery after PLEX
• Complete, n (%) 19 (41.3)• Partial, n (%) 18 (39.13)• None, n (%) 9 (19.56)
Abbreviations: PLEX – plasma exchange; min - minimum; max - maximum; SD – stan-
dard deviation; n – number; % - percentage.
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4. Discussion
The majority of the published studies have in common the inclusion
of patients with MS experiencing with aggressive diseases and severe
relapses (Weiner et al., 1989; Weinshenker, 1999). The demographic
characteristics of our population were similar to those described in
most published studies, with a greater proportion of RRMS subtype
(84.8%) and female gender (76.09%). However, these patients had also
a very aggressive disease, with high mean relapse rate in the previous
year (1.1) and accumulated disability with median EDSS of 2.25. Also,
23.91% of the patients were already treated with immunosuppressive
drugs. The high increase in median EDSS during relapse was related to
the type of symptoms experienced by the patients (mainly motor), since
EDSS highly relies on motor function disability. The majority of cases
with available brain MRI showed gadolinium enhancing lesions
(68.75%), and if spinal MRI was available this number would probably
be even higher. Even considering the patients without MS previously
diagnosed, the relapse that led to PLEX was very severe (median EDSS
during relapse of 3.5), and patients did not have an adequately response
to corticosteroids. In all the cases, PLEX was used as a second-line
treatment after corticosteroids, in order to improve recovery and avoid
residual deficits.
The mean number of PLEX sessions in our population (7.39 sessions
every other day) was comparable to other studies previously described
(Weinshenker, 1999; Keegan et al., 2002; Llufriu et al., 2009; Ehler
et al., 2015). Although good results were achieved in one study with
lower number of PLEX sessions (range 3–5) (Bennetto et al., 2004), in
our population there was a significant difference towards greater re-
covery with higher number of PLEX sessions. These results endorse the
need to adjust the number of sessions to the specific clinic situation in
order to achieve a better income.
The majority of our patients improved after PLEX, with complete
recover of neurological disability achieved in 41.30% of the cases and
partial recovery in 39.13%. This corroborate the results of previous
studies, where recovery rates of ranging from 44.1% to 72.2% have
been reported (Weinshenker, 1999; Keegan et al., 2002; Bennetto et al.,
2004; Llufriu et al., 2009; Ehler et al., 2015).
We also found that the EDSS achieved with PLEX treatment ap-
peared to be stable after one year. This has been previously reported in
some studies (Weinshenker, 1999; Llufriu et al., 2009), but not all,
(Keegan et al., 2005) and may have several explanations. We could
speculate that PLEX is associated with a lasting immunomodulatory
effect. However, it is reasonably to attribute part of this stability to a
switch or an escalation in the disease modifying treatment after the
severe relapse. In fact, 47.82% of our patients who were already under
MS treatment switched or escalated treatment, and 45.65% of our po-
pulation was treated with natalizumab or fingolimod after this relapse.
Some studies have highlighted some predictors of good response
after PLEX such as male sex, retained reflexes (Keegan et al., 2002),
gadolinium enhancing lesions in MRI (Ehler et al., 2015), early initia-
tion of PLEX (Keegan et al., 2002; Llufriu et al., 2009). In our study we
did not find a significant relation between these or other variables, as in
another study (Keegan et al., 2005), except for the number of PLEX
sessions as previously discussed. In fact, regarding time to PLEX since
relapse onset, patients experienced disability recovery even when it was
performed a long time after the relapse (83.33% during the first month,
60% during the second month, 75% during the third month and even
the patient who had PLEX after 4 months experienced complete re-
covery), as it was already previously described (Bennetto et al., 2004).
The mechanism of action of PLEX in MS has been explored. Some
patients seem to respond promptly to PLEX, while other do not respond
at all. To explain this dichotomy, some authors propose that biological
factors such as MS immunopathology heterogeneity between patients
could contribute to differences in PLEX response Keegan et al. (2005).
Four immunopathological patterns of demyelination in early multiple
sclerosis lesions have been described: in pattern I T-cell/macrophage-
associated demyelination occurs; pattern II is characterised by im-
munoglobulin deposition and complement activation with antibody/
complement-associated demyelination; pattern III is defined by a distal
oligodendrogliopathy; and pattern IV is characterised by oligoden-
drocyte degeneration in periplaque white matter (Lucchinetti et al.,
2000). In one study who particularly investigated the response to PLEX
according to immunopathological pattern, all patients with pattern II
pathology experienced moderate-to-marked improvement, compared to
none of the remaining patients with different patterns Keegan et al.
(2005). This selective response suggests that the mechanism of action of
PLEX relies on removal of immunoglobulins, complement factors, cy-
tokines, and immune complexes, and probably not as much on T-cell
and macrophage inflammation which is similar across all three im-
munopathological patterns (Keegan et al., 2005) In fact, the success of
PLEX in other presumed humorally mediated disorders such as neuro-
myelitis optica support this assumption (Keegan et al., 2005).
A minority of our patients experienced some side effects related to
PLEX, most of them easily manageable and not requiring PLEX dis-
continuation. This finding was comparable previous descriptions, in
which the majority of adverse events were incidental or related to the
patient's underlying illness (Weinshenker, 1999). Common adverse ef-
fects described include anaemia and symptomatic hypotension
(Weinshenker, 1999; Keegan et al., 2002; Llufriu et al., 2009). Heparin-
associated thrombocytopenia has been described in 2 patients (Keegan
et al., 2002), bacteraemia due to infection of their central venous line
was also described in 2 patients (concomitant vein thrombose in one
patient) and a rash successfully resolved with oral corticosteroids was
described in one patient (Llufriu et al., 2009). In one study, central IV
catheter placement was necessary in 44.1% of the patients (Keegan
et al., 2002).
The limitations of our study are mostly related to the retrospective
nature of the data collection. Moreover, it represents a single-centred,
observational and nonrandomized study, with a small population in-
cluded and without of a control group.
In our study, we have contributed to establishing the effectiveness
of PLEX regarding the recovery from severe relapses.
5. Conclusion
Our results support the use of PLEX in severe relapses unresponsive
to corticosteroids. The treatment was effective and relatively safe for
most of our patients. Considering our results and the available state of
art, we agree it should considered in the case of a relapse without
complete recovery after corticosteroids.
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